Ironwood Pharmaceuticals | IRWD - Cost Of Sales


Ironwood Pharmaceuticals reported $29.83M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Almirall EUR 191.5M 2.29M Dec/2025
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amarin USD 26.05M 1.41M Dec/2025
Ardelyx USD 4.81M 6.04M Mar/2026
Astellas Pharma JPY 129.43B 19.7B Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Charles River Laboratories USD 716.51M 5.76M Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
MacroGenics USD 9.53M 585K Mar/2026
Moderna USD 955M 503M Mar/2026
Myriad Genetics USD 63M 1.1M Dec/2025
Pacira USD 50.74M 3.89M Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Takeda JPY 560.54B 159.39B Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024